Table 3.
Characteristics and outcomes of individual patients with Philadelphia chromosome-positive advanced myeloid leukemia treated with venetoclax and tyrosine kinase inhibitor-based regimens.
| Pt No. | Age (yr) | Diagnosis | No. prior chemo | No. prior TKI | ABL Mut. | Ph+ meta (%)† | Bcr-Abl PCR (%)‡ | Regimen | TKI | Response MRD by FCM | CG Respo nse | MRD (PCR, %)‡ | FU mo | Relapse | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Philadelphia-chromosome positive acute myeloid leukemia | |||||||||||||||
| 1 | 21 | Refractory AML | 5 | 0 | Neg | 100 | 11.20 | DEC 10d | PON | CRi MRD+ | CCyR | 5.34 | 8.2 | Y | SCT > Dead |
| 2 | 47 | Refractory AML | 6 | 0 | ND | 5 | 7.05 | CPX-351+ Gilteritinib | PON | Hypocellular marrow | IS | 2.5 | 2.7 | N | SCT > Dead |
| 3 | 73 | Relapsed AML | 3 | 2 | Neg | 0 | 0.03 | DEC 5d | PON | MLFS | 0.02 | 1.4 | NA | Dead | |
| 4 | 29 | Refractory AML | 5 | 0 | ND | 0 | 0.06 | DEC 10d | DAS | NR | NA | NA | 1.8 | NA | Dead |
| 5 | 50 | Refractory AML | 6 | 1 | Neg | 20 | 8.20 | CIA | PON | NR | NA | NA | 2.4 | NA | Dead |
| 6 | 24 | Refractory AML | 4 | 0 | ND | 0 | 0.49 | FIA | PON | NR | NA | NA | 2.0 | NA | Dead |
| 7 | 70 | Refractory AML | 2 | 1 | Neg | 30 | 17.01 | DEC 10d + Gilteritinib | PON | CR MRD+ | IS | 7.12 | 9.2 | N | SCT > Alive |
| Chronic myeloid leukemia – myeloid blast phase | |||||||||||||||
| 1 | 42 | Refractory MBP | 4 | 1 | Neg | 100 | 100 | DEC 10d | DAS | CRi MRD+ | IS | 100 | 5.9 | N | Dead |
| 2 | 60 | Transformed CP | 2 | 1 | E355G | 100 | 100 | DEC 5d | BOS | CRi MRD− | PCyR | 23.7 | 2.7 | Unk | Dead |
| 3 | 34 | Transformed CP | 4 | 2 | T315I | 100 | 100 | CLIA2 | PON | CRi | CCyR | 0.23 | 2.8 | Y | Alive |
| 4 | 26 | Relapsed MBP | 5 | 2 | Neg | 100 | 8.00 | DEC 10d | PON | CRi MRD− | CCyR | 0 | 12.3 | Y | SCT > Dead |
| 5 | 65 | Relapsed MBP | 6 | 3 | Neg | 86 | 100 | DEC 5d | NIL | ED | NA | NA | 0.2 | NA | Dead |
| 6 | 30 | Refractory MBP | 8 | 3 | ND | 100 | 0.58 | Cladribine + HiDAC | DAS | NR | NA | NA | 13.7 | NA | Dead |
| 7 | 26 | Refractory MBP | 5 | 3 | E255K | 100 | 71.74 | CIA | PON | NR | NA | NA | 1.5 | NA | Dead |
| 8 | 61 | Transformed CP | 3 | 3 | Neg | IS | 9.42 | CLIA2 | PON | PR MRD− | NA | 0 | 10.2 | N | SCT > Alive |
| 9 | 75 | Transformed CP | 2 | 2 | Neg | 93 | 48.16 | DEC 10d | DAS | CRi MRD− | CCyR | 0.01 | 6.6 | N | Alive |
MBP: chronic myeloid leukemia-myeloid blast phase, CP: chronic phase, DEC: decitabine, CLIA2: cladribine, idarubicin, cytarabine, HiDAC: high dose cytarabine, CIA: clofarabine, idarubicin, cytarabine, PON: ponatinib, DAS: dasatinib, BOS: bosutinib, NIL: nilotinib, CR: complete remission, CRi: CR with incomplete hematologic recovery, PR: partial response of extramedullary disease on positron-emission tomography/computed tomography (PET/CT) MRD: minimal residual disease, ED: early death, NR: no response, NA: not applicable N: no, Neg=negative, Unk: unknown, lost to follow up, Y: yes, NA: not applicable, SCT: stem cell transplantation, FU: follow up, IS: insufficient sample, ND=not done.
Metaphases harboring t(9;21), reported as a percentage of karyotyped metaphases
BCR-ABL1 RT-PCR reported as the percentage of BCR-ABL1 to ABL1 transcripts. CCyR = complete cytogenetic response = 0% Ph+ metaphases, PCyR = partial cytogenetic response = 1–35% Ph+ metaphases